References
  1. Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Gonçalves O, et al. Behçet’s disease—a contemporary review. J Autoimmun. (2009) 32:178–88.
  2. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behcet’s disease. Autoimmun Rev. (2012) 11:687–98.
  3. Duzgun N, Ates ¸ A, Aydintug OT, et al. Characteristics of vascular involvement in Behcet’s disease. Scand J Rheumatol. 2006;35:65–68.
  4. Park SJ, Park MJ, Park S, Lee ES, Lee DY. Integrative metabolomics of plasma and PBMCs identifies distinctive metabolic signatures in Behçet’s disease. Arthritis Res Ther. 2023 Jan 7;25(1):5.
  5. Zhang F, Zhang Y, Zhao W, et al. Metabolomics for biomarker discovery in the diagnosis,prognosis, survival and recurrence of colorectal cancer: a systematic review. Oncotarget.2017 May 23;8(21):35460-35472.
  6. International Study Group for Behcet’s Disease. Criteria for diagnosis of Behcet’s disease. Lancet. 1990;335:1078–108
  7. Hamuryudan V, Fresko I, Direskeneli H, et al. Evaluation of the Turkish translation of a disease activity form for Behc¸et’s syndrome. Rheumatology (Oxford). 1999;38:734–736.
  8. Kocak E, Nemutlu E, Kir S, Sagiroglu M, Ozkul C. Integrative proteomics and metabolomics approach to elucidate the antimicrobial effect of simvastatin on Escherichia coli. Biomed Chromatogr. 2021;35(10):e5180.
  9. Gonulalan EM, Nemutlu E, Bayazeid O, Kocak E, Yalcin FN, Demirezer LO. Metabolomics and proteomics profiles of some medicinal plants and correlation with BDNF activity. Phytomedicine. 2020;74.
  10. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s disease. N Engl J Med. 1999; 341:1284–1291. PMID: 10528040
  11. Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H. Vascular involvement in Behçet’s syndrome: a retrospective analysis of associations and the time course. Rheumatology (Oxford). 2014 Nov;53(11):2018-22.
  12. O’Duffy JD. Vasculitis in Behcet’s disease. Rheum Dis Clin N Am. 1990;16(2): 423–31
  13. Cakmak OS, Seyahi E, Kantarci F, et al. Venous severity assessment in Behc¸et’s syndrome. Clin Exp Rheumatol. 2010;28:S-139.
  14. Guleria, A.; Pratap, A.; Dubey, D.; Rawat, A.; Chaurasia, S.; Sukesh, E.; Phatak, S.; Ajmani, S.; Kumar, U.; Khetrapal, C.L.; et al. NMR based serum metabolomics reveals a distinctive signature in patients with Lupus Nephritis. Sci. Rep. 2016, 6, 35309.
  15. Van Wietmarschen, H.A.; Dai, W.; van der Kooij, A.J.; Reijmers, T.H.; Schroen, Y.; Wang, M.; Xu, Z.; Wang, X.; Kong, H.; Xu, G.; et al. Characterization of rheumatoid arthritis subtypes using symptom profiles, clinical chemistry and metabolomics measurements. PLoS ONE 2012, 7, e44331
  16. Wang, W.; Yang, G.J.; Zhang, J.; Chen, C.; Jia, Z.Y.; Li, J.; Xu, W.D. Plasma, urine and ligament tissue metabolite profiling reveals potential biomarkers of ankylosing spondylitis using NMR-based metabolic profiles. Arthritis Res. Ther. 2016, 18, 244.
  17. Zheng W, Wu X, Goudarzi M, Shi J, Song W, Li C, Liu J, Chen H, Zhang X, Zeng X, Li HH. Metabolomic alterations associated with Behçet’s disease. Arthritis Res Ther. 2018 Sep 24;20(1):214.
  18. Bender, DA. Amino acid metabolism. John Wiley & Sons, Ltd; 2012. Nitrogen metabolism.; p. 1-65.
  19. Åslund F, Beckwith J. Bridge over troubled waters: Sensing stress by disulfide bond formation. Cell. 1999; 96:751–753.
  20. Isik A, Koca SS, Ustundag B, Selek S. Decreased total antioxidant response and increased oxidative stress in Behcet’s disease. Tohoku J Exp Med.  2007;212:133–41.
  21. Born TL, Blanchard JS. Enzyme-catalyzed acylation of homoserine: mechanistic characterization of the Escherichia coli metA-encoded homoserine transsuccinylase. Biochemistry. 1999 Oct 26;38(43):14416-23.
  22. Kumar, Akhilesh; Bachhawat, Anand K. (2012). ”Pyroglutamic acid: throwing light on a lightly studied metabolite” (PDF). Current Science. 102 (2): 288–297
  23. Cole, S. P., and Deeley, R. G. (2006) Transport of glutathione and glutathi-one conjugates by MRP1. Trends Pharmacol. Sci. 27, 438–446
  24. Morgan, B., Ezerin ̵̧a, D., Amoako, T. N., Riemer, J., Seedorf, M., et al. (2013)Multiple glutathione disulfide removal pathways mediate cytosolic redoxhomeostasis. Nat. Chem. Biol. 9, 119–125
  25. Kromhout, Daan; et al. (1995). ”Dietary Saturated and transFatty Acids and Cholesterol and 25-Year Mortality from Coronary Heart Disease: The Seven Countries Study”. Preventive Medicine24  (3): 308–315.
  26. Yücel Ç, Omma A, Sertoğlu E, Sezer S, Turhan T, Özgürtaş T. Evaluation of atherogenic laboratory markers in Behçet’s disease patients with vascular involvement. Arch Med Sci. 2019 Oct 27;16(3):531-537.
  27. Ruderman NB, Berger M. The formation of glutamine and alanine in skeletal muscle. J Biol Chem 1974;249:5500
  28. Holecek M, Skopec F, Skalska H, Sprongl L. Effect of alanyl-glutamine on leucine and protein metabolism in endotoxemic rats. JPEN 2000;24:215
  29. Smith RJ, Wilmore WW. Glutamine nutrition and requirements. JPEN 1990; 14(suppl):94
  30. de Oliveira Santos, R.; da Silva Cardoso, G.; da Costa Lima, L.; de Sousa Cavalcante, M.L.; Silva, M.S.; Cavalcante, A.K.M.; Severo, J.S.; de Melo Sousa, F.B.; Pacheco, G.; Alves, E.H.P.; et al. L-Glutamine and Physical Exercise Prevent Intestinal Inflammation and Oxidative Stress Without Improving Gastric Dysmotility in Rats with Ulcerative Colitis. Inflammation 2021, 44, 617–632.
  31. Jia, C.J.; Dai, C.L.; Zhang, X.; Cui, K.; Xu, F.; Xu, Y.Q. Alanyl-glutamine dipeptide inhibits hepatic ischemia-reperfusion injury in rats. World J. Gastroenterol. 2006, 12, 1373–1378.
  32. Szijarto, A.; Hahn, O.; Batmunkh, E.; Stangl, R.; Kiss, A.; Lotz, G.; Schaff, Z.; Vali, L.; Blazovics, A.; Gero, D.; et al. Short-term alanyl-glutamine dipeptide pretreatment in liver ischemia-reperfusion model: Effects on microcirculation and antioxidant status in rats. Clin. Nutr. 2007, 26, 640–648.
  33. K. Takada, T. Nakane, K. Masuda, and H. Ishii, “Ursolic acid and oleanolic acid, members of pentacyclic triterpenoid acids, suppress TNF-𝛼-induced E-selectin expression by cultured umbilical vein endothelial cells,” Phytomedicine, vol. 17, no. 14, pp. 1114–1119, 2010.
  34. K. Y. Kim, K. M. Lim, J. Y. Noh et al., “Novel antiplatelet activity of protocatechuic acid through the inhibition of high shear stress-induced platelet aggregation,” Journal of Pharmacology and ExperimentalTherapeutics, vol. 343, no. 3, pp. 704–711, 2012
  35. Tang X, Liu J, Dong W, Li P, Li L, Lin C, Zheng Y, Hou J, Li D. The cardioprotective effects of citric Acid and L-malic Acid on myocardial ischemia/reperfusion injury. Evid Based Complement Alternat Med. 2013;2013:820695.
  36. Srinivasulu C, Ramgopal M, Ramanjaneyulu G, Anuradha CM, Suresh Kumar C. Syringic acid (SA) ‒ A Review of Its Occurrence, Biosynthesis, Pharmacological and Industrial Importance. Biomed Pharmacother. 2018 Dec;108:547-557.
  37. Cobb J, Eckhart A, Motsinger-Reif A, Carr B, Groop L, Ferrannini E. α-Hydroxybutyric Acid Is a Selective Metabolite Biomarker of Impaired Glucose Tolerance. Diabetes Care. 2016 Jun;39(6):988-95.
  38. Elbein AD, Pan YT, Pastuszak I, Carroll D: New insights on trehalose: a multifunctional molecule. Glycobiology 2003, 13:17R–27R.
  39. Jain NK, Roy I: Effect of trehalose on protein structure. Protein Sci 2009, 18:24–36
  40. Sertoglu E, Omma A, Yucel C, Colak S, Sandıkcı SC, Ozgurtas T. The relationship of serum VEGF and sVEGFR-1 levels with vascular involvement in patients with Behçet’s disease. Scand J Clin Lab Invest. 2018 Oct;78(6):443-449